Matinas BioPharma Holdings Inc. (AMEX:MTNB) saw an upside of 3.05% to $0.17 after adding $0.01 on Tuesday. The 5-day average trading volume is 626,832 shares of the company’s common stock. It has gained $0.2000 in the past week and touched a new high 3 times within the past 5 days. An average of 1,057,728 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 700,509.
MTNB’s 1-month performance is -55.78% or -$0.2301 on its low of $0.1103 reached on 08/10/23. The company’s shares have touched a 52-week low of $0.11 and high of $0.89, with the stock’s rally to the 52-week high happening on 04/20/23. YTD, MTNB has lost -66.20% or -$0.3301 and has reached a new high 13 times. However, the current price is down -81.01% from the 52-week high price.
Valuation Metrics
MTNB stock has a beta of 2.08. Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 8.69.
Matinas BioPharma Holdings Inc.’s quick ratio for the period ended June 29 was 9.30. The trailing 12-month EBITDA margin is -743.16%. The firm’s gross profit as reported stood at $27.78 million against revenue of $3.19 million.
Earnings Surprise
For the quarterly period ending June 29 this year, Net income grew 2.31% to -$6.06 million, while revenue of -$5.51 million was 9.08% off the previous quarter. Analysts expected MTNB to announce -$0.03 per share in earnings in its latest quarter, but it posted -$0.03, representing a 0.00% surprise. EBITDA for the quarter stood at more than -$5.9 million. MTNB stock balance sheet for the quarter ending June 29 shows that total liabilities totaled 6.17 million, with total debt at $3.85 million. Shareholders hold equity totaling $217.26 million.
Let’s look briefly at Matinas BioPharma Holdings Inc. (MTNB) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 21 August was 19.73% to suggest the stock is trending oversold, with historical volatility in this time period at 256.37%.
The stock’s 5-day moving average is $0.1658, reflecting a +4.94% or $0.0080 change from its current price. MTNB is currently trading -57.53% above its 20-day SMA, -62.62% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 by -54.35% and SMA200 by-78.35%.
Stochastic %K and %D was 21.87% and 20.85% and the average true range (ATR) pointed at 0.0318. The RSI (14) points at 22.96%, while the 14-day stochastic is at 23.76% with the period’s ATR at 0.0331. The stock’s 9-day MACD Oscillator is pointing at -0.0030 and -0.0618 on the 14-day charts.
Analyst Ratings
In the most recent analyst report for Matinas BioPharma Holdings Inc. (AMEX: MTNB), Piper Sandler downgraded it to a Neutral rating. They previously had an Overweight rating on the stock.
